We have located links that may give you full text access.
Incidence and risk of attention-deficit hyperactivity disorder in children with amblyopia: a nationwide cohort study.
Clinical & Experimental Ophthalmology 2019 January 21
IMPORTANCE: The association between visual deficits and attention disorders has been reported but remains unproven.
BACKGROUND: The objective of this study was to evaluate the risk of attention-deficit hyperactivity disorder (ADHD) in children with amblyopia.
DESIGN: Population-based, cohort study.
PARTICIPANTS: The dataset from the Taiwan National Health Insurance Research Database in 2000-2010.
METHODS: A total of 6817 patients aged <18 years with newly diagnosed amblyopia were identified. Four age-matched and sex-matched controls without amblyopia were included for each patient, i.e., 27,268 controls.
MAIN OUTCOME MEASURES: The primary outcome was the risk of ADHD. The secondary outcomes were age at ADHD onset and use of ADHD medication.
RESULTS: During a mean observation period of 7.18 years, the incidence of ADHD per 1000 person-years was 7.02 in the amblyopia group and 4.61 in the control group (P<0.0001). The ADHD risk in the amblyopia group was 1.81 times that in the control group (hazard ratio 1.81; 95% confidence interval 1.59-2.06). After stratification by amblyopia subtype, the greatest risk was in the deprivation type (hazard ratio 2.14; 95% confidence interval 1.56-2.92) followed by the strabismic (hazard ratio 2.09; 95% confidence interval 1.15-3.79) and refractive (hazard ratio 1.76; 95% confidence interval 1.54-2.02) types. Age at ADHD onset was younger in the amblyopia group (median 8.14 versus 8.45 years; P=0.0096). The average duration of neuropsychiatric medication was comparable between groups (P=0.98).
CONCLUSIONS AND RELEVANCE: The ADHD risk is higher in children with amblyopia.
BACKGROUND: The objective of this study was to evaluate the risk of attention-deficit hyperactivity disorder (ADHD) in children with amblyopia.
DESIGN: Population-based, cohort study.
PARTICIPANTS: The dataset from the Taiwan National Health Insurance Research Database in 2000-2010.
METHODS: A total of 6817 patients aged <18 years with newly diagnosed amblyopia were identified. Four age-matched and sex-matched controls without amblyopia were included for each patient, i.e., 27,268 controls.
MAIN OUTCOME MEASURES: The primary outcome was the risk of ADHD. The secondary outcomes were age at ADHD onset and use of ADHD medication.
RESULTS: During a mean observation period of 7.18 years, the incidence of ADHD per 1000 person-years was 7.02 in the amblyopia group and 4.61 in the control group (P<0.0001). The ADHD risk in the amblyopia group was 1.81 times that in the control group (hazard ratio 1.81; 95% confidence interval 1.59-2.06). After stratification by amblyopia subtype, the greatest risk was in the deprivation type (hazard ratio 2.14; 95% confidence interval 1.56-2.92) followed by the strabismic (hazard ratio 2.09; 95% confidence interval 1.15-3.79) and refractive (hazard ratio 1.76; 95% confidence interval 1.54-2.02) types. Age at ADHD onset was younger in the amblyopia group (median 8.14 versus 8.45 years; P=0.0096). The average duration of neuropsychiatric medication was comparable between groups (P=0.98).
CONCLUSIONS AND RELEVANCE: The ADHD risk is higher in children with amblyopia.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond.Journal of Clinical Medicine 2024 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app